Identifying reliable biomarkers for Hsp90 inhibition can help in selecting patients who are more likely to benefit from this therapy and in monitoring treatment response. Some potential biomarkers include the levels of Hsp70, which are often upregulated in response to Hsp90 inhibition, and changes in the levels of specific client proteins. Ongoing research aims to validate these and other biomarkers to enhance the efficacy of Hsp90-targeted therapies.
